Published small studies show some participants achieving stabilised or slightly improved bone density, but 'success' definitions vary widely—some use any halt to density loss, others require measurable gain. Across trials, roughly 40–60% of treated participants showed some positive marker response, though fracture-risk reduction has not been formally demonstrated in controlled settings.
A review of registered clinical trials identified 14 completed or published studies in osteoporosis using cell-based approaches, predominantly with placental MSCs, alongside 2 currently recruiting trials. Trial sizes have ranged from 20 to 120 participants. Several small studies report modest improvements in bone mineral density (typically 3–8% change from baseline over 12–24 months) and some reduction in fracture markers, though methodological heterogeneity limits direct comparison. No large, multi-centre, phase III efficacy trial has yet reported.
Sono un candidato? → · Osteoporosis & Bone Health: full overview → · Costo Osteoporosi e Salute Ossea → · Cost →
Rivisto medicalmente dal team editoriale di StemCellAtlas con Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) della clinica partner Stem Plus (Sofia), rispetto alle linee guida ISSCR, FDA e EMA. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita